Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

W. Stöhr; T. Langer; A. Kremers; S. Bielack; A. Lamprecht-Dinnesen; E. Frey; J. D. Beck

doi:10.1081/CNV-200055951

Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

W. Stöhr, T. Langer, A. Kremers, S. Bielack, A. Lamprecht-Dinnesen, E. Frey, J. D. Beck^*

^*Corresponding author for this work

Clinic of Pediatric and Adolescent Medicine

62 Citations (Scopus)

Abstract

The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m²) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m², almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.

Original language	English
Journal	Cancer Investigation
Volume	23
Issue number	3
Pages (from-to)	201-207
Number of pages	7
ISSN	0735-7907
DOIs	https://doi.org/10.1081/CNV-200055951
Publication status	Published - 2005

Funding

This study was supported by ‘‘Deutsche Krebshilfe.’’ Below is a list of participating centers (and the number of study patients). Supporters include both children’s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children’s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children’s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children’s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children’s Hospital, Karlsruhe (1) Prof. Dr. D. Körholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. Jürgens, University Hospital for Children, Münster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, Tübingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. Dölken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Access to Document

10.1081/CNV-200055951

Cite this

@article{e557500a5df44bbf9c2425a8991636fc,

title = "Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system",

abstract = "The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51\% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.",

author = "W. St{\"o}hr and T. Langer and A. Kremers and S. Bielack and A. Lamprecht-Dinnesen and E. Frey and Beck, \{J. D.\}",

note = "Funding Information: This study was supported by {\textquoteleft}{\textquoteleft}Deutsche Krebshilfe.{\textquoteright}{\textquoteright} Below is a list of participating centers (and the number of study patients). Supporters include both children{\textquoteright}s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children{\textquoteright}s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children{\textquoteright}s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children{\textquoteright}s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children{\textquoteright}s Hospital, Karlsruhe (1) Prof. Dr. D. K{\"o}rholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. J{\"u}rgens, University Hospital for Children, M{\"u}nster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, T{\"u}bingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. D{\"o}lken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1) Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2005",

doi = "10.1081/CNV-200055951",

language = "English",

volume = "23",

pages = "201--207",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "3",

}

TY - JOUR

T1 - Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

AU - Stöhr, W.

AU - Langer, T.

AU - Kremers, A.

AU - Bielack, S.

AU - Lamprecht-Dinnesen, A.

AU - Frey, E.

AU - Beck, J. D.

N1 - Funding Information: This study was supported by ‘‘Deutsche Krebshilfe.’’ Below is a list of participating centers (and the number of study patients). Supporters include both children’s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children’s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children’s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children’s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children’s Hospital, Karlsruhe (1) Prof. Dr. D. Körholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. Jürgens, University Hospital for Children, Münster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, Tübingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. Dölken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1) Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2005

Y1 - 2005

N2 - The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.

AB - The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.

UR - https://www.scopus.com/pages/publications/18944370353

U2 - 10.1081/CNV-200055951

DO - 10.1081/CNV-200055951

M3 - Journal articles

C2 - 15945505

AN - SCOPUS:18944370353

SN - 0735-7907

VL - 23

SP - 201

EP - 207

JO - Cancer Investigation

JF - Cancer Investigation

IS - 3

ER -

Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this